Literature DB >> 26632267

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency.

Michal Kovac1,2, Claudia Blattmann3,4, Sebastian Ribi1, Jan Smida5,6, Nikola S Mueller7, Florian Engert8,9,10, Francesc Castro-Giner2, Joachim Weischenfeldt11, Monika Kovacova12, Andreas Krieg13, Dimosthenis Andreou14, Per-Ulf Tunn14, Hans Roland Dürr15, Hans Rechl16, Klaus-Dieter Schaser17, Ingo Melcher18, Stefan Burdach6, Andreas Kulozik4, Katja Specht19, Karl Heinimann20, Simone Fulda8,9,10, Stefan Bielack3, Gernot Jundt1, Ian Tomlinson2, Jan O Korbel11, Michaela Nathrath5,6,21, Daniel Baumhoer1.   

Abstract

Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has historically complicated driver gene discovery. Here we sequence exomes of 31 tumours and decipher their evolutionary landscape by inferring clonality of the individual mutation events. Exome findings are interpreted in the context of mutation and SNP array data from a replication set of 92 tumours. We identify 14 genes as the main drivers, of which some were formerly unknown in the context of osteosarcoma. None of the drivers is clearly responsible for the majority of tumours and even TP53 mutations are frequently mapped into subclones. However, >80% of osteosarcomas exhibit a specific combination of single-base substitutions, LOH, or large-scale genome instability signatures characteristic of BRCA1/2-deficient tumours. Our findings imply that multiple oncogenic pathways drive chromosomal instability during osteosarcoma evolution and result in the acquisition of BRCA-like traits, which could be therapeutically exploited.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26632267      PMCID: PMC4686819          DOI: 10.1038/ncomms9940

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   17.694


  39 in total

1.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

2.  The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

Authors:  Victoria J Weston; Ceri E Oldreive; Anna Skowronska; David G Oscier; Guy Pratt; Martin J S Dyer; Graeme Smith; Judy E Powell; Zbigniew Rudzki; Pamela Kearns; Paul A H Moss; A Malcolm R Taylor; Tatjana Stankovic
Journal:  Blood       Date:  2010-08-25       Impact factor: 22.113

3.  Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma.

Authors:  Alexander B Mohseny; Chris Tieken; Pieter A van der Velden; Karoly Szuhai; Carlos de Andrea; Pancras C W Hogendoorn; Anne-Marie Cleton-Jansen
Journal:  Genes Chromosomes Cancer       Date:  2010-12       Impact factor: 5.006

Review 4.  RECQ DNA helicases and osteosarcoma.

Authors:  Linchao Lu; Weidong Jin; Hao Liu; Lisa L Wang
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

5.  Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.

Authors:  Trevor Hay; Helen Jenkins; Owen J Sansom; Niall M B Martin; Graeme C M Smith; Alan R Clarke
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

6.  Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

Authors:  Malcolm A Smith; C Patrick Reynolds; Min H Kang; E Anders Kolb; Richard Gorlick; Hernan Carol; Richard B Lock; Stephen T Keir; John M Maris; Catherine A Billups; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton
Journal:  Clin Cancer Res       Date:  2014-12-10       Impact factor: 12.531

7.  Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome.

Authors:  Lisa L Wang; Anu Gannavarapu; Claudia A Kozinetz; Moise L Levy; Richard A Lewis; Murali M Chintagumpala; Ramon Ruiz-Maldanado; Jose Contreras-Ruiz; Christopher Cunniff; Robert P Erickson; Dorit Lev; Maureen Rogers; Elaine H Zackai; Sharon E Plon
Journal:  J Natl Cancer Inst       Date:  2003-05-07       Impact factor: 13.506

8.  Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.

Authors:  Todd A Hopkins; Yan Shi; Luis E Rodriguez; Larry R Solomon; Cherrie K Donawho; Enrico L DiGiammarino; Sanjay C Panchal; Julie L Wilsbacher; Wenqing Gao; Amanda M Olson; DeAnne F Stolarik; Donald J Osterling; Eric F Johnson; David Maag
Journal:  Mol Cancer Res       Date:  2015-07-27       Impact factor: 5.852

9.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

Authors:  Ana M Mendes-Pereira; Sarah A Martin; Rachel Brough; Afshan McCarthy; Jessica R Taylor; Jung-Sik Kim; Todd Waldman; Christopher J Lord; Alan Ashworth
Journal:  EMBO Mol Med       Date:  2009-09       Impact factor: 12.137

10.  TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.

Authors:  Sebastian Ribi; Daniel Baumhoer; Kristy Lee; Audrey S M Teo; Babita Madan; Kang Zhang; Wendy K Kohlmann; Fei Yao; Wah Heng Lee; Qiangze Hoi; Shaojiang Cai; Xing Yi Woo; Patrick Tan; Gernot Jundt; Jan Smida; Michaela Nathrath; Wing-Kin Sung; Joshua D Schiffman; David M Virshup; Axel M Hillmer
Journal:  Oncotarget       Date:  2015-04-10
View more
  113 in total

1.  Genome variation across cancers scales with tissue stiffness - an invasion-mutation mechanism and implications for immune cell infiltration.

Authors:  Charlotte R Pfeifer; Cory M Alvey; Jerome Irianto; Dennis E Discher
Journal:  Curr Opin Syst Biol       Date:  2017-04-27

2.  Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.

Authors:  Abhik Bandyopadhyay; Edward Favours; Doris A Phelps; Vanessa Del Pozo; Samson Ghilu; Dias Kurmashev; Joel Michalek; Aron Trevino; Denis Guttridge; Cheryl London; Kenji Hirotani; Ling Zhang; Raushan T Kurmasheva; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2017-10-28       Impact factor: 3.167

3.  Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma.

Authors:  Laurie Sorenson; Yanfen Fu; Tressa Hood; Sarah Warren; Troy A McEachron
Journal:  Oncoimmunology       Date:  2019-06-27       Impact factor: 8.110

Review 4.  Challenges and Opportunities for Childhood Cancer Drug Development.

Authors:  Peter J Houghton; Raushan T Kurmasheva
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

Review 5.  [Is there a magic bullet for sarcomas? : Personalised treatment for maligant tumours of bone and soft tissue].

Authors:  S Scheipl; B Liegl-Atzwanger; J Szkandera; B Rinner; C Viertler; J Friesenbichler; M Bergovec; A Leithner
Journal:  Orthopade       Date:  2019-09       Impact factor: 1.087

Review 6.  Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group.

Authors:  Ryan D Roberts; Michael M Lizardo; Damon R Reed; Pooja Hingorani; Jason Glover; Wendy Allen-Rhoades; Timothy Fan; Chand Khanna; E Alejandro Sweet-Cordero; Thomas Cash; Michael W Bishop; Meenakshi Hegde; Aparna R Sertil; Christian Koelsche; Lisa Mirabello; David Malkin; Poul H Sorensen; Paul S Meltzer; Katherine A Janeway; Richard Gorlick; Brian D Crompton
Journal:  Cancer       Date:  2019-07-29       Impact factor: 6.860

Review 7.  Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.

Authors:  Claudia M Hattinger; Serena Vella; Elisa Tavanti; Marilù Fanelli; Piero Picci; Massimo Serra
Journal:  Pharmacogenomics       Date:  2016-11-24       Impact factor: 2.533

Review 8.  Alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.

Authors:  Xiaolei Ren; Chao Tu; Zhenchu Tang; Ruofei Ma; Zhihong Li
Journal:  Oncol Lett       Date:  2018-03-22       Impact factor: 2.967

Review 9.  Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.

Authors:  Wei Wang; Hua-Fu Zhao; Teng-Fei Yao; Hao Gong
Journal:  Invest New Drugs       Date:  2018-10-24       Impact factor: 3.850

Review 10.  Advancing therapy for osteosarcoma.

Authors:  Jonathan Gill; Richard Gorlick
Journal:  Nat Rev Clin Oncol       Date:  2021-06-15       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.